IL6 and diabetes mellitus: Experimental evidence shows that sinomenine can reversibly reverse the upward trend of ICAM-1 and interleukin (IL)-6 in a dose-dependent manner, and notably, chronic 6-week administration significantly ameliorated elevated fasting blood glucose levels (FBGLs) in STZ-induced diabetes rats in a dose-dependent manner, while also improving other metabolic and renal function parameters without significant hepatotoxicity (Zhu et al., 2021).